Early adopters of 6-month levofloxacin as rifampicin-resistant tuberculosis preventive treatment regimen in the WHO European Region, 2023
Tuberculosis (TB) preventive treatment (TPT) is crucial for preventing infection with Mycobacterium tuberculosis from progressing to TB disease, especially among people in high-risk groups. The expansion of novel TPT regimens for drug-susceptible TB is a notable advancement in TB care. However, mana...
Saved in:
| Main Author: | Andrei Dadu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Centre for Disease Prevention and Control
2025-07-01
|
| Series: | Eurosurveillance |
| Subjects: | |
| Online Access: | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.30.2500210 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes
by: Wang Nenhan, et al.
Published: (2025-05-01) -
Levofloxacin (Tavanic) in Complex Therapy of Tuberculosis
by: G. B. Sokolova, et al.
Published: (2020-05-01) -
Insights from the 2024 WHO Global Tuberculosis Report – More Comprehensive Action, Innovation, and Investments required for achieving WHO End TB goals
by: Delia Goletti, et al.
Published: (2025-01-01) -
Evaluating the cost-effectiveness of levofloxacin therapy for household contacts of multidrug-resistant tuberculosis in VietnamResearch in context
by: Tasnim Hasan, et al.
Published: (2025-08-01) -
TB prevention activities in the WHO European Region
by: A. Matteelli, et al.
Published: (2024-08-01)